Successful patterns of maintenance therapy in human common cancer

doi:10.3760/cma.j.issn.1673-422X.2014.09.005

Abstract

Zhang Baihong, Yue Hongyun. Successful patterns of maintenance therapy in human common cancer[J]. Journal of International Oncology, 2014, 41(8): 655-658.

［1］ Gerber DE, Schiller JH. Maintenance chemotherapy for advanced nonsmallcell lung cancer: new life for an old idea［J］. J Clin Oncol, 2013, 31(8): 1009-1020. ［2］ André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in lowincome and middleincome countries?［J］. Lancet Oncol, 2013, 14(6): e239-248. ［3］ Loven D, Hasnis E, Bertolini F, et al. Lowdose metronomicchemotherapy: from past experience to new paradigms in the treatment of cancer［J］. Drug Discov Today, 2013, 18(34): 193-201. ［4］ Granovetter M. Maintenance therapy improves survival of NSCLC patients［J］. Lancet Oncol, 2013, 14(9): e347. ［5］ PazAres L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial［J］. Lancet Oncol, 2012, 13(3): 247-255. ［6］ PazAres LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(23): 2895-2902. ［7］ Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmallcell lung cancer: AVAPERL (MO22089)［J］. J Clin Oncol, 2013, 31(24): 3004-3011. ［8］ Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced nonsmallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3EMCJMEN): results from a randomised, doubleblind, phase 3 study［J］. Lancet Oncol, 2012, 13(3): 292-299. ［9］ Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(34): 4349-4357. ［10］ Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage Ⅲ nonsmallcell lung cancer (START): a randomised, doubleblind, phase 3 trial［J］. Lancet Oncol, 2014, 15(1): 5968. ［11］ Park YH, Jung KH, Im SA, et al. Phase Ⅲ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as firstline chemotherapy: KCSGBR0702［J］. J Clin Oncol, 2013, 31(14): 1732-1739. ［12］ Fedele P, Marino A, Orlando L, et al. Efficacy and safety of lowdose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer［J］. Eur J Cancer, 2012, 48(1): 24-29. ［13］ Fabi A, Russillo M, Ferretti G, et al. Maintenance bevacizumab beyond firstline paclitaxel plus bevacizumab in patients with Her2negative hormone receptorpositive metastatic breast cancer: efficacy in combination with hormonal therapy［J］. BMC Cancer, 2012, 12: 482. ［14］ Pagani O, Gelber S, Colleoni M, et al. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 1393 and 1493［J］.Breast Cancer Res Treat, 2013, 142(2): 455-459. ［15］ Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(1): 29-37. ［16］ Rosati G, Avallone A, Aprile G, et al. XELOX and bevacizumab followed by singleagent bevacizumab as maintenance therapy as firstline treatment in elderly patients with advanced colorectal cancer: the boxe study［J］. Cancer Chemother Pharmacol, 2013, 71(1): 257-264. ［17］ Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase Ⅲ 'stop and Go' study resultsa Turkish Oncology Group Trial［J］. Oncology, 2013, 85(6): 328-335. ［18］ Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer［J］. Int J Clin Oncol, 2012, 17(5): 430-440. ［19］ Barton MK. Small reduction in quality of life seen with bevacizumabmaintenance in patients with ovarian cancer［J］. CA Cancer J Clin, 2013, 63(4): 219-220. ［20］ Vergote IB, Jimeno A, Joly F, et al. Randomized phase Ⅲ study of erlotinib versus observation in patients with no evidence of disease progression after firstline platinbased chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of CancerGynaecological Cancer Group, and Gynecologic Cancer Intergroup Study［J］. J Clin Oncol, 2014, 32(4): 320-326. ［21］ Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer［J］. N Engl J Med, 2012, 366(15): 1382-1392. ［22］ Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib［J］. Onco Targets Ther, 2013, 6: 1197-1206. ［23］ Vergote IB, Chekerov R, Amant F, et al. Randomized, phase Ⅱ, placebocontrolled, doubleblind study with and without enzastaurin in combination with paclitaxel and carboplatin as firstline treatment followed by maintenance treatment in advanced ovarian cancer［J］. J Clin Oncol, 2013, 31(25): 3127-3132. ［24］ Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase Ⅲ trial of the AGO OVAR, COGI, GINECO, and GEICOthe MIMOSA study［J］. J Clin Oncol, 2013, 31(12): 1554-1561. ［25］ Palacio S, LoaizaBonilla A, Kittaneh M, et al. Successful use of trastuzumab with anthracyclinebased chemotherapy followed by trastuzumab maintenance in patients with advanced HER2positive gastric cancer［J］. Anticancer Res, 2014, 34(1): 301-306. ［26］ Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase Ⅱ randomised trial［J］. Eur J Cancer, 2013, 49(17): 3609-3615.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[15]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.

Successful patterns of maintenance therapy in human common cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments